These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38327765)

  • 1. Clinical research on RSV prevention in children and pregnant women: progress and perspectives.
    Gong X; Luo E; Fan L; Zhang W; Yang Y; Du Y; Yang X; Xing S
    Front Immunol; 2023; 14():1329426. PubMed ID: 38327765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
    Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
    J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.
    Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF;
    N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants.
    Steff AM; Cadieux-Dion C; de Lannoy G; Prato MK; Czeszak X; André B; Ingels DC; Louckx M; Dewé W; Picciolato M; Maleux K; Fissette L; Dieussaert I
    Hum Vaccin Immunother; 2020 Jun; 16(6):1327-1337. PubMed ID: 31951765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priorities for developing respiratory syncytial virus vaccines in different target populations.
    Drysdale SB; Barr RS; Rollier CS; Green CA; Pollard AJ; Sande CJ
    Sci Transl Med; 2020 Mar; 12(535):. PubMed ID: 32188721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.
    Blunck BN; Rezende W; Piedra PA
    Expert Rev Vaccines; 2021 Apr; 20(4):351-364. PubMed ID: 33733995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?].
    Novoa Pizarro JM; Lindemann Tappert BC; Luchsinger Farías VR; Vargas Munita SL
    Andes Pediatr; 2023 Dec; 94(6):672-680. PubMed ID: 38329302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.
    Simões EAF; Center KJ; Tita ATN; Swanson KA; Radley D; Houghton J; McGrory SB; Gomme E; Anderson M; Roberts JP; Scott DA; Jansen KU; Gruber WC; Dormitzer PR; Gurtman AC
    N Engl J Med; 2022 Apr; 386(17):1615-1626. PubMed ID: 35476650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
    Frenkel LD; Gaur S; Bellanti JA
    Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
    [No Abstract]   [Full Text] [Related]  

  • 14. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
    Dieussaert I; Hyung Kim J; Luik S; Seidl C; Pu W; Stegmann JU; Swamy GK; Webster P; Dormitzer PR
    N Engl J Med; 2024 Mar; 390(11):1009-1021. PubMed ID: 38477988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Atwell JE; Lutz CS; Sparrow EG; Feikin DR
    Vaccine; 2022 Jul; 40(32):4361-4370. PubMed ID: 35725783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines.
    Limaye RJ; Singh P; Fesshaye B; Karron RA
    BMC Pregnancy Childbirth; 2024 Mar; 24(1):221. PubMed ID: 38539077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.